About Denovium
Denovium is a company based in San Diego (United States) founded in 2018 by Imad Ajjawi was acquired by AbSci in January 2021. Denovium offers products and services including Integrated Drug Creation Platform, AI Drug Creation, and AI Target Discovery. Denovium operates in a competitive market with competitors including Zephyr AI, Precisionlife, Chemify, Transaction Data Systems and RevolKa, among others.
- Headquarter San Diego, United States
- Founders Imad Ajjawi
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Absci Corp
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Denovium
Denovium offers a comprehensive portfolio of products and services, including Integrated Drug Creation Platform, AI Drug Creation, and AI Target Discovery.
AI platform for designing and optimizing biologics to treat diseases faster
Iterative AI and lab cycles for biologics development and validation
Uses reverse immunology to find novel targets for drug creation
People of Denovium
Unlock access to complete
Unlock access to complete
Funding Insights of Denovium
Detailed funding history for Denovium
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Denovium
Denovium has secured backing from 1 investor. Prominent investors backing the company include AbSci.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
AI-based technology is used for recombinant protein production in therapeutics.
|
Locked | Locked | Locked |
Investor details for Denovium
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Denovium
Investment portfolio details for Denovium
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Denovium
Detailed financials for Denovium
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Denovium Comparisons
Peer comparison for Denovium
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Denovium
Denovium operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Zephyr AI, Precisionlife, Chemify, Transaction Data Systems and RevolKa, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of AI development services for biopharma sector
|
|
| Locked | Locked | Locked |
AI-enabled platforms for drug discovery and precision medicine are developed.
|
|
| Locked | Locked | Locked |
Software development services are provided for pharmaceutical and materials research.
|
|
| Locked | Locked | Locked |
Software development services are provided to the biopharma sector.
|
|
| Locked | Locked | Locked |
AI development services are provided for the biopharma sector.
|
|
| Locked | Locked | Locked |
Drug discovery and design are enabled by a cloud-based platform.
|
Detailed competitors of Denovium
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Denovium
Complete news archive for Denovium
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Denovium
Denovium was founded in 2018.
Denovium is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Denovium was founded in 2018 and is based in San Diego, United States. AI-driven methods and solutions are developed for the biopharma sector. Operations focus on applying artificial intelligence to enhance research and development processes in biotechnology and pharmaceuticals. Services include computational tools tailored for drug discovery and data analysis. The company is led by co-founder Imad Ajjawi.
Denovium offers Integrated Drug Creation Platform, AI Drug Creation, and AI Target Discovery.
Denovium has 1 investor. Key investors include AbSci.